Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 1.33 is in line with its 5-year average of 1.33, near the low end of its 5-year range (0.09–13.45).
As of the fiscal period ended Tuesday, June 30, 2026. 1.57% below its 12-month average of 1.35.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 1.33.
CURRENT RATIO
1.33
CURRENT RATIO AVG TTM
1.35
CURRENT RATIO AVG 3Y
1.11
CURRENT RATIO AVG 5Y
1.33
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-1.57%
CURRENT VS 3Y AVG
+19.64%
CURRENT VS 5Y AVG
+0.26%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.75
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
-64.51%
vs the sector median at left
Market Cap
$114.55M
Current Ratio
6.49
TTM Avg
6.44
3Y Avg
8.52
5Y Avg
8.53
Market Cap
$116.35M
Current Ratio
13.40
TTM Avg
10.04
3Y Avg
7.53
5Y Avg
8.95
Market Cap
$113.32M
Current Ratio
3.36
TTM Avg
3.23
3Y Avg
4.24
5Y Avg
6.08
Market Cap
$112.81M
Current Ratio
3.81
TTM Avg
1.94
3Y Avg
1.36
5Y Avg
2.38
Market Cap
$111.89M
Current Ratio
2.00
TTM Avg
1.45
3Y Avg
1.62
5Y Avg
1.71
Market Cap
$118.84M
Current Ratio
13.55
TTM Avg
17.30
3Y Avg
10.78
5Y Avg
9.73
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lucid Diagnostics Inc. (LUCD) | $115.30M | 1.33 | 1.35 | 1.11 | 1.33 |
| Caribou Biosciences, Inc. (CRBU)vs › | $114.55M | 6.49 | 6.44 | 8.52 | 8.53 |
| Coya Therapeutics, Inc. (COYA)vs › | $116.35M | 13.40 | 10.04 | 7.53 | 8.95 |
| MaxCyte, Inc. (MXCT)vs › | $114.08M | 12.26 | 9.59 | 11.55 | 11.23 |
| Genelux Corporation (GNLX)vs › | $113.89M | 2.39 | 3.50 | 2.69 | 1.97 |
| Foghorn Therapeutics Inc. (FHTX)vs › | $113.32M | 3.36 | 3.23 | 4.24 | 6.08 |
| Unicycive Therapeutics, Inc. (UNCY)vs › | $112.81M | 3.81 | 1.94 | 1.36 | 2.38 |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $111.89M | 2.00 | 1.45 | 1.62 | 1.71 |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.84M | 13.55 | 17.30 | 10.78 | 9.73 |
| BGM Group Ltd. (BGM)vs › | $119.26M | 1.25 | 2.31 | 3.27 | 2.89 |
Current Ratio
1.33
Quick Ratio
1.31
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 1.33 |
| 2026-03-31 | 1.07 |
| 2025-12-31 | 1.31 |
| 2025-09-30 | 1.90 |
| 2025-06-30 | 1.15 |
| 2025-03-31 | 0.75 |
| 2024-12-31 | 1.07 |
| 2024-09-30 | 1.18 |
| 2024-06-30 | 1.75 |
| 2024-03-31 | 1.38 |
| 2023-12-31 | 0.75 |
| 2023-09-30 | 0.90 |
| 2023-06-30 | 1.34 |
| 2023-03-31 | 1.78 |
| 2022-12-31 | 2.89 |
| 2022-09-30 | 3.08 |
| 2022-06-30 | 4.55 |
| 2022-03-31 | 3.71 |
| 2021-12-31 | 13.45 |
| 2021-09-30 | 0.09 |
| 2021-06-30 | 0.16 |
| 2021-03-31 | 0.07 |
| 2020-12-31 | 0.09 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
| 2019-12-31 | 0.06 |
| 2018-12-31 | 0.02 |
